Proto Script Pharmaceutical

Proto Script Pharmaceutical Financing Cash Flow

The Net Financing Cash Flow of Proto Script Pharmaceutical (PSCR) as of Nov 4, 2026 is 48,940.00 USD. In the previous year, Net Financing Cash Flow was -54,070.00 USD — a change of -190.51% (higher).

Financing Cash Flow

48,940.00USD

YoY

-190.51%

Last updated:

Net Financing Cash Flow of Proto Script Pharmaceutical is 2016 48,940.00 USD. Net Financing Cash Flow of Proto Script Pharmaceutical was 2015 -54,070.00 USD. It decreases by -190.51% higher compared to the previous year.

The Proto Script Pharmaceutical Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2014
73,732.00 USD
Jan 1, 2015
-54,070.00 USD
Jan 1, 2016
48,940.00 USD
The Proto Script Pharmaceutical Financing Cash Flow history
YEARFinancing Cash FlowYoY
48,940.00USD-190.51%
-54,070.00USD-173.33%
73,732.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Proto Script Pharmaceutical Stock analysis

What does Proto Script Pharmaceutical do? Proto Script Pharmaceutical Corp is an American biotechnology company specializing in the development and manufacture of innovative, high-quality drugs. The company is focused on researching new breakthrough technologies in drug manufacturing to find potential cures and treat diseases. Their business model is based on producing medications that are highly effective and of high quality while also being cost-effective and patient-friendly. They collaborate closely with biotechnology companies and academic institutions to acquire the best technologies and develop effective and innovative drugs. They have products in the areas of neurology, endocrine health, and oncology. They have also entered into partnerships with other companies to expand and further develop their products. Overall, Proto Script Pharmaceutical Corp is a groundbreaking company in the biotechnology field with decades of experience in drug development and a commitment to improving the lives of millions of people worldwide. Proto Script Pharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proto Script Pharmaceutical stock

Net Financing Cash Flow of Proto Script Pharmaceutical is 48,940.00 USD in 2016.

Net Financing Cash Flow of Proto Script Pharmaceutical changed from -54,070.00 USD to 48,940.00 USD, representing a -190.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Proto Script Pharmaceutical since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Proto Script Pharmaceutical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Proto Script Pharmaceutical

All Key Metrics — Proto Script Pharmaceutical